59,284 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 59,284 shares of the company's stock, valued at approximately $2,073,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.13% of Omnicell as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Principal Financial Group Inc. grew its stake in Omnicell by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock valued at $8,553,000 after purchasing an additional 6,288 shares during the period. Jane Street Group LLC grew its position in Omnicell by 7.4% during the fourth quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock valued at $2,417,000 after buying an additional 3,725 shares during the period. Invesco Ltd. increased its holdings in Omnicell by 2.4% during the fourth quarter. Invesco Ltd. now owns 219,453 shares of the company's stock worth $9,770,000 after buying an additional 5,063 shares during the last quarter. Mariner LLC increased its holdings in Omnicell by 16.1% during the fourth quarter. Mariner LLC now owns 9,075 shares of the company's stock worth $404,000 after buying an additional 1,261 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Omnicell by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock worth $247,628,000 after acquiring an additional 28,573 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Price Performance

NASDAQ:OMCL traded down $1.25 during mid-day trading on Friday, hitting $29.76. 742,476 shares of the stock traded hands, compared to its average volume of 568,361. The business's 50-day moving average price is $29.24 and its 200 day moving average price is $33.26. The company has a quick ratio of 1.23, a current ratio of 1.38 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.39 billion, a PE ratio of 64.70, a price-to-earnings-growth ratio of 8.67 and a beta of 0.76. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. The firm had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The business's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $0.51 EPS. On average, analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on OMCL shares. Wells Fargo & Company raised their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 12th. Finally, Bank of America upped their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $45.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.